The UCLA-Boston University Lung Cancer Biomarker Development Laboratory (UCLA-BU BDL) is a multidisciplinary, transiational research program designed to develop and characterize new biomarkers and assays through transiational research in the molecular pathogenesis of lung cancer. By drawing from the vast academic and clinical resources at our two institutions, the UCLA-BU BDL will advance new discoveries and transform them into early detection tools for lung cancer. This discovery-translational continuum is facilitated by a multidisciplinary team of UCLA and BU investigators whose expertise encompasses biological sciences, biostatistics, bioinformatics, translational and clinical pulmonary medicine, pathology and oncology. By joining a seamless collaboration between these investigators, we anticipate that this team will develop biomarkers whose application will disrupt major barriers in early detection and diagnosis of lung cancer.
The aims of our research that will achieve these goals Include: 1) Identify mRNA and microRNA expression profiles in the airways and protein profiles in peripheral blood that can serve as non-invasive diagnostic biomarkers for lung cancer. 2) Develop airway and peripheral blood-based biomarkers capable of preclinical detection of lung cancer among high-risk current and former smokers. 3) Using prospectively collected cohorts, evaluate the classification accuracy of the diagnostic and preclinical detection biomarkers identified in the airway and blood in Alms 1 and 2. We hypothesize that chronic Injury, inflammation and aberrant epithelial repair result in a field of injury that supports lung carcinogenesis and that the molecular, biochemical and cellular events associated with these processes will allow for the detection of early stage lung cancer in non-invasively collected biospecimens, including the mouth, nose and blood. Our proposed studies utilize novel and complementary approaches to solve the clinical problem of early detection of lung cancer in high-risk patients. We are well positioned to perform these studies given: a) the synergy of our groups and institutions which bring together extensive experience in lung cancer chemoprevention and early detection studies;b) our expertise in gene expression profiling and computational biology, c) our access to unique prospective cohorts of high-risk current and former smokers and those with suspect lung cancer in which intra/extra-thoracic airway and blood samples are being collected;d) our preliminary data showing feasibility of the proposed airway and blood biomarker studies as well as the existing collaborations between our investigators and e) the powerful potential of combined multi-compartment, non-invasive testing.
|Hong, Candice Sun; Graham, Nicholas A; Gu, Wen et al. (2016) MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep 14:1590-601|
|Whitney, Duncan H; Elashoff, Michael R; Porta-Smith, Kate et al. (2015) Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy. BMC Med Genomics 8:18|
|Silvestri, Gerard A; Vachani, Anil; Whitney, Duncan et al. (2015) A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N Engl J Med 373:243-51|
|Campbell, Joshua D; Liu, Gang; Luo, Lingqi et al. (2015) Assessment of microRNA differential expression and detection in multiplexed small RNA sequencing data. RNA 21:164-71|
|Grant, Jeanette L; Fishbein, Michael C; Hong, Long-Sheng et al. (2014) A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis. Cancer Prev Res (Phila) 7:150-60|
|Ooi, Aik T; Gower, Adam C; Zhang, Kelvin X et al. (2014) Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila) 7:487-95|
|Krysan, Kostyantyn; Kusko, Rebecca; Grogan, Tristan et al. (2014) PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res 12:765-74|
|Liclican, Elvira L; Walser, Tonya C; Hazra, Saswati et al. (2014) Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy. Cancer Prev Res (Phila) 7:845-55|
|Brothers, John F; Hijazi, Kahkeshan; Mascaux, Celine et al. (2013) Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med 11:168|
|Kachroo, Puja; Lee, Mi-Heon; Zhang, Ling et al. (2013) IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res 32:97|
Showing the most recent 10 out of 16 publications